Treatment of proliferative lupus nephritis: a changing landscape.
Grootscholten et al. report a randomized controlled trial comparing azathioprine plus intravenous methylprednisolone and oral prednisolone (AZA group) with intermittent intravenous cyclophosphamide and oral prednisolone (CY group) in patients with proliferative lupus nephritis. AZA-treated patients were more likely to develop non-sustained doubling of their serum creatinine, although not significantly so, and significantly more likely to have a relapse of their nephritis than CY-treated patients.
Adu
D
D
Department of Nephrology, Queen Elizabeth Hospital, Birmingham, UK. dwoms@blueyonder.co.uk
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000097:blood / Q000188:drug therapy*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone; D003404:Creatinine; D009173:Mycophenolic Acid; D001379:Azathioprine; D008775:Methylprednisolone